Vega Yolanda, Delgado Elena, Fernández-García Aurora, Cuevas Maria Teresa, Thomson Michael M, Montero Vanessa, Sánchez Monica, Sánchez Ana Maria, Pérez-Álvarez Lucia
Unidad de Biología y Variabilidad de VIH, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
PLoS One. 2015 May 26;10(5):e0125699. doi: 10.1371/journal.pone.0125699. eCollection 2015.
Our objectives were to carry out an epidemiological surveillance study on transmitted drug resistance (TDR) among individuals newly diagnosed of HIV-1 infection during a nine year period in Spain and to assess the role of transmission clusters (TC) in the propagation of resistant strains. An overall of 1614 newly diagnosed individuals were included in the study from January 2004 through December 2012. Individuals come from two different Spanish regions: Galicia and the Basque Country. Resistance mutations to reverse transcriptase inhibitors (RTI) and protease inhibitors (PI) were analyzed according to mutations included in the surveillance drug-resistance mutations list updated in 2009. TC were defined as those comprising viruses from five or more individuals whose sequences clustered in maximum likelihood phylogenetic trees with a bootstrap value ≥90%. The overall prevalence of TDR to any drug was 9.9%: 4.9% to nucleoside RTIs (NRTIs), 3.6% to non-nucleoside RTIs (NNRTIs), and 2.7% to PIs. A significant decrease of TDR to NRTIs over time was observed [from 10% in 2004 to 2% in 2012 (p=0.01)]. Sixty eight (42.2%) of 161 sequences with TDR were included in 25 TC composed of 5 or more individuals. Of them, 9 clusters harbored TDR associated with high level resistance to antiretroviral drugs. T215D revertant mutation was transmitted in a large cluster comprising 25 individuals. The impact of epidemiological networks on TDR frequency may explain its persistence in newly diagnosed individuals. The knowledge of the populations involved in TC would facilitate the design of prevention programs and public health interventions.
我们的目标是在西班牙进行一项为期九年的关于新诊断出的HIV-1感染者中传播性耐药(TDR)的流行病学监测研究,并评估传播簇(TC)在耐药菌株传播中的作用。2004年1月至2012年12月期间,共有1614名新诊断的个体纳入该研究。这些个体来自西班牙的两个不同地区:加利西亚和巴斯克地区。根据2009年更新的监测耐药突变列表中包含的突变,分析了对逆转录酶抑制剂(RTI)和蛋白酶抑制剂(PI)的耐药突变。TC被定义为包含来自五个或更多个体的病毒,其序列在最大似然系统发育树中聚类,自展值≥90%。对任何药物的TDR总体患病率为9.9%:对核苷类RTI(NRTI)为4.9%,对非核苷类RTI(NNRTI)为3.6%,对PI为2.7%。观察到随时间推移对NRTI的TDR显著下降[从2004年的10%降至2012年的2%(p=0.01)]。161个具有TDR的序列中有68个(42.2%)包含在由5个或更多个体组成的25个TC中。其中,9个簇含有与抗逆转录病毒药物高水平耐药相关的TDR。T215D回复突变在一个包含25个个体的大簇中传播。流行病学网络对TDR频率的影响可能解释了其在新诊断个体中的持续存在。了解参与TC的人群将有助于预防计划和公共卫生干预措施的设计。